Volume 8, Issue 2 (4-2026)
pbp 2026, 8(2): 170-184 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghdaki M, Kamkari S. Application of Nanoparticles in the Treatment of Ovarian Cancer: A Review of Emerging Strategies for Targeted Therapy. pbp 2026; 8 (2) :170-184
URL: http://pbp.medilam.ac.ir/article-1-394-en.html
URL: http://pbp.medilam.ac.ir/article-1-394-en.html
1- Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,Sima.kamkari@gmail.com
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract: (308 Views)
Objective: Ovarian cancer remains highly lethal, primarily due to late-stage diagnosis and the limitations of conventional therapies, which are often associated with systemic toxicity and limited tumor specificity. Nanoparticles, owing to their nanoscale dimensions, high surface-to-volume ratio, and capacity for surface functionalization, offer improved drug delivery and precise tumor targeting. This review provides a comprehensive summary of the principal types of nanoparticles employed in ovarian cancer therapy, with an emphasis on their mechanisms of action and therapeutic efficacy.
Methods: This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.
Results: A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric CoFe₂O₄@BaTiO₃ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplatforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs–Tx–HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B–responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.
Conclusion: Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients’ quality of life.
Methods: This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.
Results: A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric CoFe₂O₄@BaTiO₃ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplatforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs–Tx–HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B–responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.
Conclusion: Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients’ quality of life.
Type of Study: Review/Systemtic review |
Subject:
Pharmacological
Received: 2025/09/23 | Accepted: 2026/01/21 | Published: 2026/01/1
Received: 2025/09/23 | Accepted: 2026/01/21 | Published: 2026/01/1
References
1. Kamkari S, Soufizadeh Balaneji S. The Role of Medicinal Plants in Relieving Menopausal Symptoms: A Traditional Iranian Medicine Perspective. Plant Biotechnol Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-382-en.html
2. Najib FS, Izanloo E, Aghdaki M, Khansalar S, Fattahi MJ, Oveisi Z, et al. Stromal Cell-Derived Factor1 Genetic Variation at Locus 801 in Patients with Endometrial Cancer. Middle East J Cancer. 2025;16(2):181-8.
3. Kamkari S, Sadat Najib F. Abortifacient Medicinal Plants: A Review of Toxic Herbs During Pregnancy. Plant Biotechnol Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-378-en.html
4. Faraji A, Aghdaki M, Hessami K, Hosseinkhani A, Roozmeh S, Asadi N, et al. Episiotomy wound healing by Commiphora myrrha and Boswellia carteri in primiparous women: A randomized controlled trial. J Ethnopharmacol. 2021;264:113396.
5. Aghdaki M, Kamkari S. Probiotics as a Therapeutic Strategy in Ovarian Cancer: Insights from Preclinical and Clinical Evidence. Plant Biotechnol Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-392-en.html
6. Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E. Global socioeconomic inequalities in breast, cervical, ovarian, and uterine cancers incidence, mortality, disability-adjusted life year’s rates: a relative concentration index analysis. BMC Womens Health. 2025;25(1):433.
7. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151-6.
8. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376-88.
9. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3-23.
10. Nomura H, Iwasa N, Yoshihama T, Nanki Y, Aoki D. Epidemiology and etiology of ovarian cancer. In: Frontiers in Ovarian Cancer Science. Singapore: Springer; 2017. p. 1-13.
11. Barber HR. Ovarian carcinoma: etiology, diagnosis, and treatment. Springer; 2012.
12. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262-7.
13. Furuya M. Ovarian cancer stroma: pathophysiology and the roles in cancer development. Cancers (Basel). 2012;4(3):701-24.
14. Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019;125:4623-9.
15. Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014;77(2):128-36.
16. Shiri S, Alizadeh K, Abbasi N. A novel technique for simultaneous determination of drugs using magnetic nanoparticles-based dispersive micro-solid-phase extraction in biological fluids and wastewaters. MethodsX. 2020;7:101040. doi:10.1016/j.mex.2020.100952
17. Ding H, Zhang J, Zhang F, Xu Y, Liang W, Yu Y. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends. Drug Deliv. 2022;29(1):3218-32.
18. Kreuter J. Nanoparticles. In: Colloidal Drug Delivery Systems. CRC Press; 2014. p. 231-53.
19. Horikoshi SA, Serpone NI. Introduction to nanoparticles. Microwaves in Nanoparticle Synthesis. 2013;1-24.
20. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10-29.
21. Guduru R, Liang P, Runowicz C, Nair M, Atluri V, Khizroev S. Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells. Sci Rep. 2013;3:2953.
22. Dominguez-Rios R, Sanchez-Ramirez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Juarez J, et al. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces. 2019;178:199-207.
23. Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, et al. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep. 2018;8:8524.
24. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release. 2010;144(3):324-31.
25. Sanchez-Salcedo S, Vallet-Regí M, Shahin SA, Glackin CA, Zink JI. Mesoporous core-shell silica nanoparticles with anti-fouling properties for ovarian cancer therapy. Chem Eng J. 2018;340:114-24.
26. Vilos C, Morales FA, Solar PA, Herrera NS, Gonzalez-Nilo FD, Aguayo DA, et al. Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials. 2013;34(16):4098-108.
27. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A. 2011;108(2):745-50.
28. Liu Y, Chen S, Sun J, Zhu S, Chen C, Xie W, et al. Folate-targeted and oxygen/indocyanine green-loaded lipid nanoparticles for dual-mode imaging and photo-sonodynamic/photothermal therapy of ovarian cancer. Mol Pharm. 2019;16(10):4104-20.
29. Kim J, Shim MK, Cho YJ, Jeon S, Moon Y, Choi J, et al. Safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279:121189.
30. Fu H, Guo X, Fang F, Zhou C, Chen Y, Zhang X, et al. STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer. J Control Release. 2025;381:113565.
31. Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M. Albendazole loaded albumin nanoparticles for ovarian cancer therapy. Eur J Nanomed. 2014;6(4):227-36.
32. Wang L, Neoh KG, Kang ET, Shuter B. Multifunctional polyglycerol-grafted Fe3O4@SiO2 nanoparticles for targeting ovarian cancer cells. Biomaterials. 2011;32(8):2166-73.
33. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, et al. Translational impact of nanoparticle–drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015;21(4):808-18.
34. Li G, Shi S, Tan J, He L, Liu Q, Fang F, et al. Highly efficient synergistic chemotherapy and magnetic resonance imaging for targeted ovarian cancer therapy using hyaluronic acid-coated coordination polymer nanoparticles. Adv Sci (Weinh). 2024;11(41):2309464.
35. Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 2018;78(21):6247-56.
36. Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20:50.
37. Risnayanti C, Jang YS, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci Rep. 2018;8:1-2.
38. Huang Y, Zhu C, Xie R, Ni M. Green synthesis of nickel nanoparticles using Fumaria officinalis as a novel chemotherapeutic drug for ovarian cancer. J Exp Nanosci. 2021;16(1):368-81.
39. Dou L, Zhang X, Zangeneh MM, Zhang Y. Efficient biogenesis of Cu2O nanoparticles using Camellia sinensis leaf extract: evaluation of cytotoxic and anti-human ovarian cancer properties. Bioorg Chem. 2021;106:104468.
40. Yuan C, Jiang B, Xu X, Wan Y, Wang L, Chen J. Anti-human ovarian cancer and cytotoxicity effects of nickel nanoparticles green-synthesized by Alhagi maurorum leaf extract. J Exp Nanosci. 2022;17(1):113-25.
41. Yuan C, Jiang B, Xu X, Wan Y, Wang L, Chen J. Anti-human ovarian cancer and cytotoxicity effects of nickel nanoparticles green-synthesized by Alhagi maurorum leaf aqueous extract. J Exp Nanosci. 2022 Dec 31;17(1):113-25.
42. Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, Huang Y. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. Nano Lett. 2020 Apr 6;20(5):3039-49.
43. Li TS, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly (ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. Eur J Pharm Sci. 2014 Feb 14;52:48-61.
44. Jiang H, Liang G, Dai M, Dong Y, Wu Y, Zhang L, Xi Q, Qi L. Preparation of doxorubicin-loaded collagen-PAPBA nanoparticles and their anticancer efficacy in ovarian cancer. Ann Transl Med. 2020 Jul;8(14):880.
45. Pires IS, Covarrubias G, Gomerdinger VF, Backlund C, Nombera Bueno E, Billingsley MM, Pryor M, Shanker A, Gordon E, Wu S, Pickering AJ. IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer. Nat Mater. 2025 Oct 31;1-3.
46. Ma Y, Zhang X, Xu X, Shen L, Yao Y, Yang Z, Liu P. STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells. PLoS One. 2015 Apr 29;10(4):e0124924.
47. Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, Chen B, Dong X, Wang Y, Lou X, Xia F. Biocompatible AIEgen/p-glycoprotein siRNA@ reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Theranostics. 2021 Jan 27;11(8):3710.
48. Shahin SA, Wang R, Simargi SI, Contreras A, Echavarria LP, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine (Lond). 2018 Jun;14(4):1381-94.
49. Gokduman K. Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study. Nanomedicine. 2019 Dec;14(24):3177.
50. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul;13(7):1750-7.
51. Dragulska SA, Acosta Santiago M, Swierczek S, Chuang L, Camacho-Vanegas O, Camacho SC, Padron-Rhenals MM, Martignetti JA, Mieszawska AJ. Synthesis and Characterization of Poly (Lactic-Co-Glycolic Acid)–Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models. Pharmaceutics. 2025 May 23;17(6):689.
52. Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, Ratcliffe J, Scoble JA, Drummond CJ, Tran N. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl Mater Interfaces. 2018 Jul 2;10(30):25174-85.
53. Michy T, Massias T, Bernard C, Vanwonterghem L, Henry M, Guidetti M, Royal G, Coll JL, Texier I, Josserand V, Hurbin A. Verteporfin-loaded lipid nanoparticles improve ovarian cancer photodynamic therapy in vitro and in vivo. Cancers (Basel). 2019 Nov 8;11(11):1760.
54. Satpathy M, Wang L, Zielinski RJ, Qian W, Wang YA, Mohs AM, Kairdolf BA, Ji X, Capala J, Lipowska M, Nie S. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. Theranostics. 2019 Jan 24;9(3):778.
55. Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine. 2014 Apr 15;9:1855-70.
56. Fraguas-Sánchez AI, Torres-Suárez AI, Cohen M, Delie F, Bastida-Ruiz D, Yart L, Martin-Sabroso C, Fernández-Carballido A. PLGA nanoparticles for the intraperitoneal administration of CBD in the treatment of ovarian cancer: In Vitro and In Ovo assessment. Pharmaceutics. 2020 May 9;12(5):439.
57. Krais A, Wortmann L, Hermanns L, Feliu N, Vahter M, Stucky S, Mathur S, Fadeel B. Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. Nanomedicine (Lond). 2014 Oct;10(7):1421-31.
58. Zhang XF, Gurunathan S. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy. Int J Nanomedicine. 2016 Aug 2;11:3655-75.
59. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm. 2010 Jun 7;7(3):775-85.
60. Ekkapongpisit M, Giovia A, Follo C, Caputo G, Isidoro C. Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups. Int J Nanomedicine. 2012 Jul 31;7:4147-58.
61. Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, Bhattacharya R, Mukherjee P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Jul 11;5(15):6453-64.
62. Correa S, Boehnke N, Barberio AE, Deiss-Yehiely E, Shi A, Oberlton B, Smith SG, Zervantonakis I, Dreaden EC, Hammond PT. Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry. ACS Nano. 2020 Jan 23;14(2):2224-37.
63. Liang X, Yang Y, Huang C, Ye Z, Lai W, Luo J, Li X, Yi X, Fan JB, Wang Y, Wang Y. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. J Control Release. 2023 Apr 1;356:691-701.
64. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011 Nov;32(33):8548-54.
65. Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, Huang Y. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. Nano Lett. 2020 Apr 6;20(5):3039-49.
66. Li TS, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly (ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. Eur J Pharm Sci. 2014 Feb 14;52:48-61.
67. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep;177(3):1053-64.
68. Wang Y, Pasternak M, Sathiyamoorthy K, Kolios MC. Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy. Biomed Opt Express. 2021 Mar 18;12(4):2171-85.
69. Al-Taie A, Özcan Bülbül E. A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches. J Drug Target. 2024 Jan 2;32(1):45-56.
70. Shim N, Jeon SI, Yang S, Park JY, Jo M, Kim J, Choi J, Yun WS, Kim J, Lee Y, Shim MK. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy. Biomaterials. 2022 Oct;289:121806.
71. Zhong YJ, Shao LH, Li YA. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy. Int J Oncol. 2013 Feb;42(2):373-83.
72. Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM. Active targeted nanoparticles for delivery of poly (ADP-ribose) polymerase (PARP) inhibitors: a preliminary review. Int J Mol Sci. 2021 Sep 25;22(19):10319.
73. Alemi SF, Pourhassan MM, Kalan ME, Mehdipour A, Aliyari SZ, Ebrahimi KA. Targeting the PI3K/Akt/mTOR signaling pathway: Applications of nanotechnology. [Journal/Year details missing]
74. Mensah LB, Morton SW, Li J, Xiao H, Quadir MA, Elias KM, Penn E, Richson AK, Ghoroghchian PP, Liu J, Hammond PT. Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer. Bioeng Transl Med. 2019 May;4(2):e10131.
75. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011 Dec;165(7):1628-51.
76. Saman S, Srivastava N, Yasir M, Chauhan I. A comprehensive review on current treatments and challenges involved in the treatment of ovarian cancer. Curr Cancer Drug Targets. 2024 Feb 1;24(2):142-66.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |